NovaBay Pharmaceuticals Statistics
Share Statistics
NovaBay Pharmaceuticals has 4.89M shares outstanding. The number of shares has increased by -83.77% in one year.
| Shares Outstanding | 4.89M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.89M |
| Failed to Deliver (FTD) Shares | 1.44K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 38.38K, so 0.79% of the outstanding shares have been sold short.
| Short Interest | 38.38K |
| Short % of Shares Out | 0.79% |
| Short % of Float | 0.79% |
| Short Ratio (days to cover) | 0.46 |
Valuation Ratios
The PE ratio is -0.09 and the forward PE ratio is -0.95.
| PE Ratio | -0.09 |
| Forward PE | -0.95 |
| PS Ratio | 0.06 |
| Forward PS | 0.2 |
| PB Ratio | 0.26 |
| P/FCF Ratio | -0.21 |
| PEG Ratio | n/a |
Enterprise Valuation
NovaBay Pharmaceuticals Inc. has an Enterprise Value (EV) of 469.86K.
| EV / Earnings | -0.05 |
| EV / Sales | 0.03 |
| EV / EBITDA | -0.1 |
| EV / EBIT | -0.09 |
| EV / FCF | -0.11 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.83.
| Current Ratio | 1.67 |
| Quick Ratio | 1 |
| Debt / Equity | 0.83 |
| Total Debt / Capitalization | 45.26 |
| Cash Flow / Debt | -1.51 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -2.91% and return on capital (ROIC) is -82.64%.
| Return on Equity (ROE) | -2.91% |
| Return on Assets (ROA) | -1.07% |
| Return on Capital (ROIC) | -82.64% |
| Revenue Per Employee | 613.58K |
| Profits Per Employee | -401.67K |
| Employee Count | 24 |
| Asset Turnover | 1.63 |
| Inventory Turnover | 2.37 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.5% in the last 52 weeks. The beta is 0.73, so NovaBay Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.73 |
| 52-Week Price Change | -87.5% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 62.81 |
| Average Volume (20 Days) | 568.64K |
Income Statement
In the last 12 months, NovaBay Pharmaceuticals had revenue of 14.73M and earned -9.64M in profits. Earnings per share was -138.65.
| Revenue | 14.73M |
| Gross Profit | 7.89M |
| Operating Income | -5.00M |
| Net Income | -9.64M |
| EBITDA | -4.80M |
| EBIT | -5.00M |
| Earnings Per Share (EPS) | -138.65 |
Balance Sheet
The company has 3.13M in cash and 2.74M in debt, giving a net cash position of 390.00K.
| Cash & Cash Equivalents | 3.13M |
| Total Debt | 2.74M |
| Net Cash | 390.00K |
| Retained Earnings | -174.85M |
| Total Assets | 3.88M |
| Working Capital | 295.00K |
Cash Flow
In the last 12 months, operating cash flow was -4.13M and capital expenditures -19.00K, giving a free cash flow of -4.15M.
| Operating Cash Flow | -4.13M |
| Capital Expenditures | -19.00K |
| Free Cash Flow | -4.15M |
| FCF Per Share | -34.46 |
Margins
Gross margin is 53.61%, with operating and profit margins of -33.97% and -65.46%.
| Gross Margin | 53.61% |
| Operating Margin | -33.97% |
| Pretax Margin | -65.46% |
| Profit Margin | -65.46% |
| EBITDA Margin | -32.6% |
| EBIT Margin | -33.97% |
| FCF Margin | -28.18% |
Dividends & Yields
NBY does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -19807.14% |
| FCF Yield | -121.66% |
Analyst Forecast
The average price target for NBY is $0.85, which is 21.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $0.85 |
| Price Target Difference | 21.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 31, 2024. It was a backward split with a ratio of 1:35.
| Last Split Date | May 31, 2024 |
| Split Type | backward |
| Split Ratio | 1:35 |
Scores
| Altman Z-Score | -67.3 |
| Piotroski F-Score | 3 |